[Form 4] Twist Bioscience Corporation Insider Trading Activity

Rhea-AI Filing Summary

Twist Bioscience insider sale to cover taxes; reporting confirms compliance. The filing shows Paula Green, SVP of Human Resources and a company officer, had 892 shares sold on 09/08/2025 at $25.76 per share to satisfy tax-withholding obligations arising from the vesting of Restricted Stock Units. After the transaction, the reporting person beneficially owned 124,837 shares, held directly. The sale is described as a mandatory "sell-to-cover" under the issuer's equity plan and therefore is not a discretionary trade by the reporting person. The Form 4 was signed by an attorney-in-fact on 09/10/2025.

Positive

• Timely disclosure: Form 4 filed and signed, showing compliance with Section 16 reporting requirements.
• Transaction was non-discretionary: Sale described as a mandatory "sell-to-cover" for RSU tax withholding, not an opportunistic trade.

Negative

• Reduction in holdings: The reporting person sold 892 shares, lowering direct beneficial ownership to 124,837 shares.
• Limited context on materiality: The filing does not state the reporting person’s total holdings across all account types, so relative impact cannot be fully assessed.

Insights

Financial Analyst

TL;DR: Routine sell-to-cover RSU tax withholding; immaterial to company fundamentals.

The filing documents a small, mandatory disposition of 892 shares at $25.76 to meet tax obligations tied to RSU vesting. Because this is a plan-directed "sell-to-cover" transaction rather than a voluntary sale, it does not indicate a change in the reporting person’s view on the company’s prospects. The remaining direct beneficial ownership of 124,837 shares maintains sizeable insider exposure. Impact on valuation or control is negligible based on the disclosed amounts.

Corporate Governance Expert

TL;DR: Filing reflects standard equity plan mechanics and timely disclosure under Section 16.

The Form 4 clearly identifies the mandatory sell-to-cover mechanism and records the post-transaction direct ownership. The submission, signed by an attorney-in-fact, meets disclosure obligations and helps preserve transparency around officer equity changes. There is no indication of an intentional, discretionary insider sale in the document, reducing governance concern from this specific transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Green Paula

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD.

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP of Human Resources

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2025		S		892(1)	D	$25.76	124,837	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Paula Green	09/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Paula Green report in the Form 4 for TWST?

The Form 4 reports a sale of 892 shares of Twist Bioscience common stock at $25.76 on 09/08/2025 to cover taxes from RSU vesting; post-transaction direct ownership is 124,837 shares.

Was this insider sale a discretionary trade or a mandatory sell-to-cover?

The filing states the sale was a mandatory 'sell-to-cover' required by the issuer's equity incentive plan to satisfy tax withholding obligations and was not a discretionary trade by the reporting person.

When was the Form 4 signed and filed?

The Form 4 is dated and signed by an attorney-in-fact on 09/10/2025 for the transaction dated 09/08/2025.

How many shares did the reporting person own after the transaction?

After the reported transaction the reporting person beneficially owned 124,837 shares, held directly.

Does the filing indicate any discretionary insider selling that could signal negative sentiment?

No. The document explicitly characterizes the sale as a sell-to-cover for RSU tax withholding, which is a routine, non-discretionary transaction.